AbbVie to submit upadacitinib to FDA after 5th trial win

AbbVie aims to submit its experimental JAK inhibitor upadacitinib for approval in moderate-to-severe rheumatoid arthritis later this year after the oral drug met all its primary and second goals in its fifth Phase 3 study.